Denali Therapeutics Inc. (DNLI) stock
DNLINasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$18.00−0.08 (-0.44%)
Close on Nov 17, 2026Market cap $2.88BP/E –Yield –
Denali Therapeutics operating cash flow
Operating cash flow is the cash the business generates from its day-to-day operations.
Denali Therapeutics's operating cash flow for the twelve months ending Jun 30, 2026 was -$434.04M. For fiscal 2025 it was -$412.60M. The highest annual figure on record is $416.15M in fiscal 2020.
Annual operating cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$412.60M | – |
| FY2024 | Dec 31, 2024 | -$347.69M | – |
| FY2023 | Dec 31, 2023 | -$357.99M | – |
| FY2022 | Dec 31, 2022 | -$244.72M | – |
| FY2021 | Dec 31, 2021 | -$211.39M | -150.8% |
| FY2020 | Dec 31, 2020 | $416.15M | – |
| FY2019 | Dec 31, 2019 | -$151.58M | -402.5% |
| FY2018 | Dec 31, 2018 | $50.12M | – |
| FY2017 | Dec 31, 2017 | -$76.64M | – |
| FY2016 | Dec 31, 2016 | -$71.91M | – |
Quarterly operating cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$97.00M | – |
| Q1 FY2026 | Mar 31, 2026 | -$131.20M | – |
| Q4 FY2025 | Dec 31, 2025 | -$98.54M | – |
| Q3 FY2025 | Sep 30, 2025 | -$107.30M | – |
| Q2 FY2025 | Jun 30, 2025 | -$75.30M | – |
| Q1 FY2025 | Mar 31, 2025 | -$131.47M | – |
| Q4 FY2024 | Dec 31, 2024 | -$83.72M | – |
| Q3 FY2024 | Sep 30, 2024 | -$59.14M | – |
| Q2 FY2024 | Jun 30, 2024 | -$91.22M | – |
| Q1 FY2024 | Mar 31, 2024 | -$113.62M | – |
| Q4 FY2023 | Dec 31, 2023 | -$98.66M | – |
| Q3 FY2023 | Sep 30, 2023 | -$87.36M | – |
| Q2 FY2023 | Jun 30, 2023 | -$113.17M | – |
| Q1 FY2023 | Mar 31, 2023 | -$58.80M | – |
| Q4 FY2022 | Dec 31, 2022 | -$72.66M | – |
| Q3 FY2022 | Sep 30, 2022 | -$57.05M | – |
| Q2 FY2022 | Jun 30, 2022 | -$42.90M | – |
| Q1 FY2022 | Mar 31, 2022 | -$72.11M | – |
| Q4 FY2021 | Dec 31, 2021 | -$65.49M | -112.7% |
| Q3 FY2021 | Sep 30, 2021 | -$41.43M | -48279.1% |
| Q2 FY2021 | Jun 30, 2021 | -$54.22M | – |
| Q1 FY2021 | Mar 31, 2021 | -$50.24M | – |
| Q4 FY2020 | Dec 31, 2020 | $513.92M | – |
| Q3 FY2020 | Sep 30, 2020 | $86.00K | – |
| Q2 FY2020 | Jun 30, 2020 | -$43.36M | – |
| Q1 FY2020 | Mar 31, 2020 | -$54.49M | – |
| Q4 FY2019 | Dec 31, 2019 | -$47.64M | -151.1% |
| Q3 FY2019 | Sep 30, 2019 | -$30.44M | – |
| Q2 FY2019 | Jun 30, 2019 | -$43.18M | – |
| Q1 FY2019 | Mar 31, 2019 | -$30.32M | -190.3% |
| Q4 FY2018 | Dec 31, 2018 | $93.19M | – |
| Q3 FY2018 | Sep 30, 2018 | -$34.82M | – |
| Q2 FY2018 | Jun 30, 2018 | -$41.82M | – |
| Q1 FY2018 | Mar 31, 2018 | $33.58M | – |
| Q4 FY2017 | Dec 31, 2017 | -$18.34M | – |
| Q3 FY2017 | Sep 30, 2017 | -$21.92M | – |
| Q2 FY2017 | Jun 30, 2017 | -$17.57M | – |
| Q1 FY2017 | Mar 31, 2017 | -$18.81M | – |
See a number that looks wrong?